24 November 2016 - Advanced pancreatic cancer patients in Scotland may benefit from a new treatment which could allow them to live twice as long as they would otherwise.

The Scottish Medicines Consortium is currently considering whether to make Onivyde available on the NHS north of the Border.

If approved, the drug - also known as pegylated liposomal irinotecan - would be prescribed to patients whose first chemotherapy treatment has not been effective or stopped working.

Onivyde was licensed for use in October but is currently only available to patients across the UK privately.

Read The Express article